Loading...
Market
Region with highest new mpox cases by end of 2024?
2
Resolution / Starting Odds
Africa • 25%
North America • 25%
Europe • 25%
Asia • 25%
Public health data from WHO or CDC
Story
FDA Approves Emergent's ACAM2000 Mpox Vaccine, Stock Soars 23%
Aug 30, 2024, 05:50 AM
The U.S. Food and Drug Administration (FDA) has approved the expanded use of Emergent BioSolutions' ACAM2000®, a live smallpox vaccine, to include individuals at high risk for mpox infection. This approval comes amid ongoing mpox outbreaks across Africa and other regions, highlighting a critical public health challenge. Following the FDA's decision, Emergent BioSolutions' stock saw a significant increase, soaring by 23%. The ACAM2000 vaccine, initially developed for smallpox, will now play a crucial role in addressing the public health challenge posed by mpox.
View original story
Similar markets
Africa • 25%
Americas • 25%
Europe • 25%
Asia • 25%
Africa • 25%
Americas • 25%
Europe • 25%
Asia • 25%
Africa • 25%
Americas • 25%
Europe • 25%
Asia • 25%
United Kingdom • 25%
Europe excluding UK • 25%
Africa • 25%
Other • 25%
Africa • 25%
Asia • 25%
Americas • 25%
Europe • 25%
Africa • 25%
Americas • 25%
Europe • 25%
Asia • 25%
Africa • 25%
Americas • 25%
Europe • 25%
Asia • 25%
North India • 25%
South India • 25%
East India • 25%
West India • 25%
Zambia • 25%
Uganda • 25%
Democratic Republic of Congo • 25%
Other • 25%
Democratic Republic of Congo • 25%
South Africa • 25%
Nigeria • 25%
Other • 25%
Democratic Republic of Congo • 25%
Uganda • 25%
Rwanda • 25%
Other • 25%
Uganda • 25%
Gabon • 25%
Neighboring Regions • 25%
Other • 25%